Last week, executive management of BioLargo’s subsidiary Clyra Medical Technologies met for the first time with the company’s newly formed Medical Advisory Board to discuss clinical trials, refine the company’s strategy for commercialization, and plan for development of additional products. This meeting comes in the wake of Clyra’s recently announced FDA 510(k) approval for its first advanced wound care product, a wound irrigation product based on the company’s proprietary antimicrobial chemistry.
The Medical Advisory Board meeting took place at the Fall 2019 Symposium for Advanced Wound Care (SAWC) in Las Vegas, a leading forum for the advancement of wound care practices and technology now in its 33rd year. The event was attended by thousands of physicians, researchers, scientists, podiatrists, wound care technology experts, and more.
Clyra’s Medical Advisory Board is comprised of over 30 experts, including medical doctors, surgeons, podiatrists, wound care researchers, and medical industry experts. Members of Clyra’s Medical Advisory Board offer Clyra unprecedented insight into the science and business of clinical wound care and provide invaluable counsel to Clyra as it prepares its first product for clinical trials and commercialization following its recent FDA approval.
To see Clyra’s Medical Advisory Board and learn about its members, visit https://www.clyramedical.com/advisoryboard
Clyra's President Steve Harrison comments on the Medical Advisory Board meeting, “We are pleased that we have been able to attract some of the best and brightest minds in diverse fields relevant to our powerful and innovative wound care products. Our Advisory Board includes world-renowned experts in wound care, infection research, orthopedic surgery, podiatry, medical product development, reimbursement and more. We look forward to a long and productive relationship with these world-class advisors, and we know our Advisory Board will play a big role in the successful commercial rollout of our advanced wound care products. Our first meeting at SAWC was a huge step toward achieving that goal”.
About Clyra Medical Technologies, Inc.
Clyra Medical Technologies, Inc., a subsidiary of BioLargo, Inc., develops best-in-class advanced wound care products designed to promote fast, effective wound healing without sacrificing tissue health or sensitivity. Clyra’s first product, a wound irrigation solution, received pre-market approval through FDA 510(k) in September, 2019. The company also owns SkinDiscTM, a revolutionary stem cell therapy product that provides unprecedented wound healing with no documented adverse reactions. Learn more at www.clyramedical.com.
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.com) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
President and CEO
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.